Business
Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study
Analysis of 35,000 patients tested with Nodify Lung® Nodule Risk Assessment in a real-world setting to be presented at CHEST 2024 and launch of a new
About this update from Biodesix, Inc.
Analysis of 35,000 patients tested with Nodify Lung® Nodule Risk Assessment in a real-world setting to be presented at CHEST 2024 and launch of a new clinical study designed to expand data package LOUISVILLE, Colo. --(BUSINESS WIRE)-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2024 in Boston, Massachusetts on Tuesday, October 8 at 10:20 am ET . The presentation will detail the experience of healthcare providers using the Nodify Lung® Nodule Risk Assessment in over 35,000 patients consecutively tested in a real-world clinical setting. Guidelines recommend that clinicians assess the risk of lung cancer in patients with new nodules to inform the next steps for the patient. Up to 80% of patients are assigned a low to moderate risk, or a 5-65% risk of lung cancer, where next steps are unclear. Biodesix Nodify Lung testing, comprised of the Nodify CDT® and Nodify XL2® blood-based lung nodule tests, is designed to reclassify the risk of lung cancer to a high (>65% risk) or very low (